Cost per response analysis of deucravacitinib versus apremilast and first-line biologics among patients with moderate to severe plaque psoriasis in the United States

Cost per response analysis of deucravacitinib versus apremilast and first-line biologics among patients with moderate to severe plaque psoriasis in the United States

Background Understanding the economic value of deucravacitinib and apremilast could assist treatment decision-making for patients with moderate to severe plaque psoriasis.Objective This study compared the cost per response (CPR) for US patients initiating deucravacitinib versus apremilast for modera...

Full description

Saved in:
Bibliographic Details
Main Authors: Sang Hee Park, Mark Lambton, Jordana Schmier, Sara Hovland, Keith Wittstock, Vardhaman Patel
Format: Article
Language:English
Published: Taylor & Francis Group 2024-12-01
Series:Journal of Dermatological Treatment
Subjects:
Cost per cumulative benefit
cost per response
protein kinase inhibitors
psoriasis
Online Access:https://www.tandfonline.com/doi/10.1080/09546634.2024.2366503
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://www.tandfonline.com/doi/10.1080/09546634.2024.2366503

Similar Items